Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Study For Third Opioid Abuse Deterrent Product
NORTHVALE, N.J., May 19, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-202, an undisclosed opioid abuse deterrent product, utilizing Elite's proprietary pharmacological abuse deterrent technology.
Help employers find you! Check out all the jobs and post your resume.